Sirukumab is a monoclonal antibody medication used to treat rheumatoid arthritis. It is used in combination with methotrexate for adults who have responded inadequately to methotrexate alone. It is administered by subcutaneous injection. Common side effects include infusion reactions, injection site reactions, and upper respiratory infections.
Sirukumab is a human monoclonal antibody medication used to treat moderate to severe rheumatoid arthritis in adults who have not responded well to other medications, such as methotrexate or tumor necrosis factor (TNF) blockers . It works by blocking the action of interleukin 6 (IL-6), a protein that plays a role in the inflammation process. Sirukumab is given as an injection under the skin (subcutaneously) every two or four weeks.
Sirukumab is a relatively new medication, and its long-term safety and efficacy are still being studied. However, it has been shown to be effective in reducing symptoms of rheumatoid arthritis, such as pain, stiffness, and swelling. It can also help to slow the progression of joint damage.
Common side effects of sirukumab include upper respiratory tract infections, injection site reactions, headache, and fatigue. More serious side effects can occur, but they are relatively rare. These include serious infections, decreased white blood cell counts, and allergic reactions.
Sirukumab is not appropriate for everyone. It should not be used by people who are allergic to it or who have a severe infection. It is also not recommended for pregnant women or women who are breastfeeding.